Dose response of two synthetic human growth hormone-releasing factors on growth hormone release in heifers and pigs.

Peticlerc D, Pelletier G, Lapierre H, Gaudreau P, Couture Y, Dubreuil P, Morisset J, Brazeau P

Journal of animal science1 Oct 1987Cited by 27 (Europe PMC)

PMID2889716DOI10.2527/jas1987.654996xPepBankPUB-02889716

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In dairy heifers and pigs, hGRF(1-29)NH2 and hGRF(1-44)NH2 stimulated GH secretion equally at all doses.
In plain wordsIn young cattle and pigs, the shorter and longer forms of this peptide raised growth hormone equally at every dose.
Peptide
Sermorelin
Outcome
No significant changeGH release at all doses (both species)
Study
dairy heifers and pigsn = 20
Comparator
hGRF (1-44)NH2
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
0, 0.067, 0.2, 0.6 and 1.8 nmol/kg body weight · intravenousAs given in this study (dairy heifers and pigs).
Source sentences
Summary
In both species, data indicated that hGRF (1-44)NH2 and hGRF (1-29)NH2 equally stimulate GH secretion at all doses.
2 context sentences(design, population, supporting numbers)
Summary · context
This study was undertaken to evaluate the biological potency of two synthetic human growth hormone-releasing factors, hGRF (1-44)NH2 and hGRF (1-29)NH2, on growth hormone (GH) release in young dairy heifers (n = 10) and pigs (n = 10).
Summary · context
In each species, the GH response to an iv injection (0, .067, .2, .6 and 1.8 nmol.kg-1 body weight) of each peptide was evaluated in a double 5 X 5 Latin square design.
Report a problemFND-0288971601
02AnimalAnimal study (in vivo)Efficacy outcome
In young dairy heifers, peak GH concentrations did not differ between hGRF(1-29)NH2 and hGRF(1-44)NH2 at any dose tested.
In plain wordsIn young dairy heifers, the peak growth hormone level was not different between the two peptide forms at any dose.
Peptide
Sermorelin
Outcome
No significant changePeak GH concentration in heifers
Study
dairy heifersn = 10
Comparator
hGRF (1-44)NH2
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
0, 0.067, 0.2, 0.6 and 1.8 nmol/kg body weight · intravenousAs given in this study (dairy heifers).
Source sentences
Summary
In dairy heifers, average peak concentrations (81.7, 94.7, 84.5 and 93.7 ng.ml-1 vs 91.5, 81.0, 94.3 and 91.6 ng.ml-1) and area under the GH response curve (3,661, 4,541, 7,196 and 6,788 ng.ml-1.min vs 3,000, 3,982, 5,639 and 6,724 ng.ml-1.min) were not different (P greater than .05) between hGRF(1-…
2 context sentences(design, population, supporting numbers)
Summary · context
This study was undertaken to evaluate the biological potency of two synthetic human growth hormone-releasing factors, hGRF (1-44)NH2 and hGRF (1-29)NH2, on growth hormone (GH) release in young dairy heifers (n = 10) and pigs (n = 10).
Summary · context
In each species, the GH response to an iv injection (0, .067, .2, .6 and 1.8 nmol.kg-1 body weight) of each peptide was evaluated in a double 5 X 5 Latin square design.
Report a problemFND-0288971602
03AnimalAnimal study (in vivo)Efficacy outcome
In young dairy heifers, the area under the GH response curve did not differ between hGRF(1-29)NH2 and hGRF(1-44)NH2.
In plain wordsIn young dairy heifers, the total growth hormone response was not different between the two peptide forms.
Peptide
Sermorelin
Outcome
No significant changeGH area under the curve in heifers
Study
dairy heifersn = 10
Comparator
hGRF (1-44)NH2
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
0, 0.067, 0.2, 0.6 and 1.8 nmol/kg body weight · intravenousAs given in this study (dairy heifers).
Source sentences
Summary
In dairy heifers, average peak concentrations (81.7, 94.7, 84.5 and 93.7 ng.ml-1 vs 91.5, 81.0, 94.3 and 91.6 ng.ml-1) and area under the GH response curve (3,661, 4,541, 7,196 and 6,788 ng.ml-1.min vs 3,000, 3,982, 5,639 and 6,724 ng.ml-1.min) were not different (P greater than .05) between hGRF(1-…
2 context sentences(design, population, supporting numbers)
Summary · context
This study was undertaken to evaluate the biological potency of two synthetic human growth hormone-releasing factors, hGRF (1-44)NH2 and hGRF (1-29)NH2, on growth hormone (GH) release in young dairy heifers (n = 10) and pigs (n = 10).
Summary · context
In each species, the GH response to an iv injection (0, .067, .2, .6 and 1.8 nmol.kg-1 body weight) of each peptide was evaluated in a double 5 X 5 Latin square design.
Report a problemFND-0288971603
04AnimalAnimal study (in vivo)Efficacy outcome
In pigs, peak GH concentrations did not differ between hGRF(1-29)NH2 and hGRF(1-44)NH2.
In plain wordsIn pigs, the peak growth hormone level was not different between the two peptide forms.
Peptide
Sermorelin
Outcome
No significant changePeak GH concentration in pigs
Study
pigsn = 10
Comparator
hGRF (1-44)NH2
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
0, 0.067, 0.2, 0.6 and 1.8 nmol/kg body weight · intravenousAs given in this study (pigs).
Source sentences
Summary
Similarly, in pigs, average peak concentrations (35.6, 38.6, 76.5 and 73.8 ng.ml-1 vs 28.7, 30.0, 41.3 and 80.8 ng.ml-1) and area under the GH curve (1,576, 1,567, 3,299 and 3,622 ng.ml-1.min vs 1,115, 1,658, 1,482 and 2,528 ng.ml-1.min) were not different (P greater than .05) between both peptides.
2 context sentences(design, population, supporting numbers)
Summary · context
This study was undertaken to evaluate the biological potency of two synthetic human growth hormone-releasing factors, hGRF (1-44)NH2 and hGRF (1-29)NH2, on growth hormone (GH) release in young dairy heifers (n = 10) and pigs (n = 10).
Summary · context
In each species, the GH response to an iv injection (0, .067, .2, .6 and 1.8 nmol.kg-1 body weight) of each peptide was evaluated in a double 5 X 5 Latin square design.
Report a problemFND-0288971604
05AnimalAnimal study (in vivo)Efficacy outcome
In pigs, the area under the GH curve did not differ between hGRF(1-29)NH2 and hGRF(1-44)NH2.
In plain wordsIn pigs, the total growth hormone response was not different between the two peptide forms.
Peptide
Sermorelin
Outcome
No significant changeGH area under the curve in pigs
Study
pigsn = 10
Comparator
hGRF (1-44)NH2
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
0, 0.067, 0.2, 0.6 and 1.8 nmol/kg body weight · intravenousAs given in this study (pigs).
Source sentences
Summary
Similarly, in pigs, average peak concentrations (35.6, 38.6, 76.5 and 73.8 ng.ml-1 vs 28.7, 30.0, 41.3 and 80.8 ng.ml-1) and area under the GH curve (1,576, 1,567, 3,299 and 3,622 ng.ml-1.min vs 1,115, 1,658, 1,482 and 2,528 ng.ml-1.min) were not different (P greater than .05) between both peptides.
2 context sentences(design, population, supporting numbers)
Summary · context
This study was undertaken to evaluate the biological potency of two synthetic human growth hormone-releasing factors, hGRF (1-44)NH2 and hGRF (1-29)NH2, on growth hormone (GH) release in young dairy heifers (n = 10) and pigs (n = 10).
Summary · context
In each species, the GH response to an iv injection (0, .067, .2, .6 and 1.8 nmol.kg-1 body weight) of each peptide was evaluated in a double 5 X 5 Latin square design.
Report a problemFND-0288971605
06AnimalAnimal study (in vivo)Mechanism
In dairy heifers, GH release after injection of hGRF(1-44)NH2 and hGRF(1-29)NH2 was biphasic at the highest dose.
In plain wordsIn young dairy heifers, growth hormone release came in two phases after the highest dose of either peptide form.
Peptide
Sermorelin
Outcome
Not applicableBiphasic GH release at highest dose in heifers
Study
dairy heifersn = 10
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
1.8 nmol/kg body weight · intravenousAs given in this study (dairy heifers).
Source sentences
Summary
A biphasic release of GH after hGRF (1-44)NH2 and hGRH (1-29)NH2 injection was observed at the highest dose in heifers.
2 context sentences(design, population, supporting numbers)
Summary · context
This study was undertaken to evaluate the biological potency of two synthetic human growth hormone-releasing factors, hGRF (1-44)NH2 and hGRF (1-29)NH2, on growth hormone (GH) release in young dairy heifers (n = 10) and pigs (n = 10).
Summary · context
In each species, the GH response to an iv injection (0, .067, .2, .6 and 1.8 nmol.kg-1 body weight) of each peptide was evaluated in a double 5 X 5 Latin square design.
Report a problemFND-0288971606
07AnimalAnimal study (in vivo)Other
In pigs, the GH response to hGRF injection was much more variable than in dairy heifers.
In plain wordsIn pigs, the growth hormone response to this peptide varied much more between animals than in young dairy heifers.
Peptide
Sermorelin
Outcome
Not applicableVariability of GH response in pigs versus heifers
Study
pigsn = 10
Comparator
Dairy heifers
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
0, 0.067, 0.2, 0.6 and 1.8 nmol/kg body weight · intravenousAs given in this study (pigs).
Source sentences
Summary
The GH response to hGRF injection was much more variable in pigs as compared with dairy heifers.
2 context sentences(design, population, supporting numbers)
Summary · context
This study was undertaken to evaluate the biological potency of two synthetic human growth hormone-releasing factors, hGRF (1-44)NH2 and hGRF (1-29)NH2, on growth hormone (GH) release in young dairy heifers (n = 10) and pigs (n = 10).
Summary · context
In each species, the GH response to an iv injection (0, .067, .2, .6 and 1.8 nmol.kg-1 body weight) of each peptide was evaluated in a double 5 X 5 Latin square design.
Report a problemFND-0288971607

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 19:08 UTC
Study results updated
Version 1
9 Oct 2026, 03:13 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.